Optic IconOptic Logo
|
SearchCollectionsBenchmarks

P+L

1 abstract

Abstract
Randomized phase II trial of pembrolizumab/lenvatinib (P+L) +/- responder fecal microbiota transplant (R-FMT) in PD-1 relapsed/refractory (R/R) cutaneous melanoma (MEL).
Org: UPMC Hillman Cancer Center, University of Pittsburgh, University of Pittsburgh Medical Center (UPMC), Nihon Medi-Physics,